DE69626610D1 - Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington. - Google Patents
Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington.Info
- Publication number
- DE69626610D1 DE69626610D1 DE69626610T DE69626610T DE69626610D1 DE 69626610 D1 DE69626610 D1 DE 69626610D1 DE 69626610 T DE69626610 T DE 69626610T DE 69626610 T DE69626610 T DE 69626610T DE 69626610 D1 DE69626610 D1 DE 69626610D1
- Authority
- DE
- Germany
- Prior art keywords
- huntington
- epilepsy
- disease
- treatment
- rapamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US833795P | 1995-12-07 | 1995-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69626610D1 true DE69626610D1 (de) | 2003-04-17 |
DE69626610T2 DE69626610T2 (de) | 2003-10-02 |
Family
ID=21731060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69626610T Expired - Fee Related DE69626610T2 (de) | 1995-12-07 | 1996-12-04 | Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington. |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP0778023B1 (de) |
JP (1) | JPH09183727A (de) |
KR (1) | KR970032856A (de) |
CN (1) | CN1112925C (de) |
AR (1) | AR008747A1 (de) |
AT (1) | ATE234095T1 (de) |
AU (1) | AU700653B2 (de) |
BR (1) | BR9605895A (de) |
CA (1) | CA2192298A1 (de) |
CZ (2) | CZ6498A3 (de) |
DE (1) | DE69626610T2 (de) |
DK (1) | DK0778023T3 (de) |
ES (1) | ES2188730T3 (de) |
HU (1) | HUP9603370A3 (de) |
IL (1) | IL119778A (de) |
MX (1) | MX9606131A (de) |
NO (1) | NO309966B1 (de) |
NZ (1) | NZ299888A (de) |
PT (1) | PT778023E (de) |
SI (1) | SI0778023T1 (de) |
SK (1) | SK154796A3 (de) |
TW (1) | TW427904B (de) |
ZA (1) | ZA9610245B (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1002535A1 (de) | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs |
US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
US6417189B1 (en) * | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
FR2806626B1 (fr) * | 2000-03-22 | 2003-11-28 | Centre Nat Rech Scient | Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues |
AU2001255406A1 (en) * | 2000-04-17 | 2001-10-30 | Gpi Nil Holdings, Inc. | Cyclic diaza compounds for treating neurodegenerative disorders |
GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
US20030176455A1 (en) * | 2002-03-13 | 2003-09-18 | Wyeth | Method of inhibiting cell death |
PL1611144T3 (pl) | 2003-04-09 | 2011-03-31 | Wyeth Llc | Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA) |
AU2004229567A1 (en) * | 2003-04-09 | 2004-10-28 | Wyeth | Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
US20070155771A1 (en) * | 2003-04-11 | 2007-07-05 | David Rubinsztein | Methods and means for treating protein conformational disorders |
US7485706B2 (en) * | 2003-07-30 | 2009-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neurodegenerative protein aggregation inhibition methods and compounds |
TW200514775A (en) | 2003-10-22 | 2005-05-01 | Wyeth Corp | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof |
ES2380779T3 (es) * | 2004-12-20 | 2012-05-18 | Wyeth Llc | Análogos de rapamicina y usos de los mismos en el tratamiento de trastornos neurológicos, proliferativos e inflamatorios |
CN101084226A (zh) | 2004-12-20 | 2007-12-05 | 惠氏公司 | 雷帕霉素衍生物及其治疗神经紊乱的用途 |
JP4857071B2 (ja) * | 2006-10-12 | 2012-01-18 | 潤平 笹部 | 筋萎縮性側策硬化症(als)の検出方法 |
EP2065038A1 (de) | 2007-11-30 | 2009-06-03 | Pharnext | Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit |
EP2135607A1 (de) | 2008-06-18 | 2009-12-23 | Pharnext | Kombination aus Pilocarpin und Methimazol zur Behandlung der Charcot-Marie-Tooth Krankheit und verwandten Erkrankungen |
CN104997774A (zh) * | 2009-04-10 | 2015-10-28 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
EP2263665A1 (de) * | 2009-06-02 | 2010-12-22 | Pharnext | Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2456437A4 (de) * | 2009-07-24 | 2013-01-09 | Inst Nat Rech Scient | Kombinationen aus curcumoiden- und mtor-hemmern für die behandlung von tauopathien |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
US9121859B2 (en) | 2012-12-04 | 2015-09-01 | Siemens Healthcare Diagnostics Inc. | Compounds and methods for determination of FKBP-binding immunosuppressant drugs |
AU2014276856B2 (en) | 2013-06-05 | 2018-11-15 | Pharnext | Stable oral solutions for combined API |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
KR20200088856A (ko) * | 2017-11-15 | 2020-07-23 | 벤더르빌트 유니버시티 | 리소좀 기능의 개선 및 퇴행성 신경 질환의 치료를 위한 방법 및 조성물 |
CN114366738A (zh) * | 2021-12-20 | 2022-04-19 | 中国人民解放军军事科学院军事医学研究院 | 雷帕霉素在促进神经干细胞扩增中的用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
JPH04230389A (ja) * | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
US5078999A (en) * | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
IL101353A0 (en) * | 1991-04-03 | 1992-11-15 | American Home Prod | Pharmaceutical compositions for treating diabetes |
DE4118740A1 (de) * | 1991-06-05 | 1992-12-10 | Schering Ag | Neue kombinationspraeparate zur behandlung des morbus parkinson |
ZA924953B (en) * | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
US5260299A (en) * | 1992-03-05 | 1993-11-09 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents |
IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
-
1996
- 1996-11-28 TW TW085114700A patent/TW427904B/zh not_active IP Right Cessation
- 1996-12-04 CZ CZ9864A patent/CZ6498A3/cs unknown
- 1996-12-04 ES ES96308786T patent/ES2188730T3/es not_active Expired - Lifetime
- 1996-12-04 DE DE69626610T patent/DE69626610T2/de not_active Expired - Fee Related
- 1996-12-04 PT PT96308786T patent/PT778023E/pt unknown
- 1996-12-04 CZ CZ963544A patent/CZ354496A3/cs unknown
- 1996-12-04 DK DK96308786T patent/DK0778023T3/da active
- 1996-12-04 SI SI9630586T patent/SI0778023T1/xx unknown
- 1996-12-04 SK SK1547-96A patent/SK154796A3/sk unknown
- 1996-12-04 AT AT96308786T patent/ATE234095T1/de not_active IP Right Cessation
- 1996-12-04 EP EP96308786A patent/EP0778023B1/de not_active Expired - Lifetime
- 1996-12-05 AU AU74178/96A patent/AU700653B2/en not_active Ceased
- 1996-12-05 NZ NZ299888A patent/NZ299888A/en unknown
- 1996-12-05 ZA ZA9610245A patent/ZA9610245B/xx unknown
- 1996-12-05 KR KR1019960062011A patent/KR970032856A/ko not_active Application Discontinuation
- 1996-12-05 MX MX9606131A patent/MX9606131A/es unknown
- 1996-12-06 CA CA002192298A patent/CA2192298A1/en not_active Abandoned
- 1996-12-06 AR ARP960105543A patent/AR008747A1/es not_active Application Discontinuation
- 1996-12-06 JP JP8326582A patent/JPH09183727A/ja active Pending
- 1996-12-06 IL IL11977896A patent/IL119778A/xx not_active IP Right Cessation
- 1996-12-06 CN CN96123098A patent/CN1112925C/zh not_active Expired - Fee Related
- 1996-12-06 BR BR9605895A patent/BR9605895A/pt not_active Application Discontinuation
- 1996-12-06 HU HU9603370A patent/HUP9603370A3/hu unknown
- 1996-12-06 NO NO965238A patent/NO309966B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2188730T3 (es) | 2003-07-01 |
CZ6498A3 (cs) | 1998-06-17 |
DE69626610T2 (de) | 2003-10-02 |
AU7417896A (en) | 1997-06-12 |
NO309966B1 (no) | 2001-04-30 |
NO965238D0 (no) | 1996-12-06 |
HU9603370D0 (en) | 1997-01-28 |
EP0778023B1 (de) | 2003-03-12 |
EP0778023A1 (de) | 1997-06-11 |
IL119778A0 (en) | 1997-03-18 |
CZ354496A3 (cs) | 1998-03-18 |
PT778023E (pt) | 2003-06-30 |
BR9605895A (pt) | 1998-08-18 |
ATE234095T1 (de) | 2003-03-15 |
MX9606131A (es) | 1997-08-30 |
HUP9603370A2 (en) | 1997-05-28 |
ZA9610245B (en) | 1998-06-05 |
IL119778A (en) | 1999-07-14 |
NZ299888A (en) | 2001-02-23 |
TW427904B (en) | 2001-04-01 |
AU700653B2 (en) | 1999-01-14 |
SK154796A3 (en) | 1997-09-10 |
HUP9603370A3 (en) | 1998-12-28 |
KR970032856A (ko) | 1997-07-22 |
SI0778023T1 (en) | 2003-08-31 |
CN1159915A (zh) | 1997-09-24 |
CN1112925C (zh) | 2003-07-02 |
CA2192298A1 (en) | 1997-06-08 |
NO965238L (no) | 1997-06-09 |
JPH09183727A (ja) | 1997-07-15 |
AR008747A1 (es) | 2000-02-23 |
DK0778023T3 (da) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69626610D1 (de) | Produkt enthaltend Rapamycin oder ausgewählte Derivate und einen NMDA- oder AMPA-Antagonisten zur Verwendung für die Behandlung von Epilepsie oder Morbus Huntington, und die Verwendung von Rapamycin oder von ausgewählten Derivaten für die Herstellung eines Medikaments für die Behandlung von Epilepsie oder Morbus Huntington. | |
DE3855525T2 (de) | Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS. | |
DE69706566T2 (de) | Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit | |
DE69626961D1 (de) | Wegwerfkleidungsstück, verfahren und vorrichtung zu dessen herstellung | |
DE309309T1 (de) | Blattfoermiges material zur haut- oder haarbehandlung, verfahren zu dessen herstellung und aus diesem material hergestellte gegenstaende. | |
PL323046A1 (en) | Procedures related to arterio-vascular and vascular transplants: method and compositions | |
EP1029540A3 (de) | Verwendung von Droloxifen zur Behandlung von cardiovaskulären Erkrankungen | |
DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
DE69532990D1 (de) | Ein zusammengesetzter gegenstand für die behandlung von dermatologischen narben, ein verfahren zur herstellung des gegenstandes und dessen verwendung | |
DE69426320D1 (de) | Verwendung von silikon/fluorsilikon kopolymeröl zur herstellung eines arzneimittels zur behandlung von augenerkrankungen | |
ATE335487T1 (de) | Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten | |
DE69429806D1 (de) | Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung | |
DE69232911D1 (de) | Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen | |
DE69003960T2 (de) | Die Verwendung von deacetyliertem Chitin zur Herstellung eines Medikamentes für die Behandlung von entzündliche Krankheiten. | |
DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
DE69620786D1 (de) | Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie | |
DE69915848D1 (de) | Verwendung von neohesperidin dc zur herstellung eines medikaments zur vorbeugung bzw. behandlung von krankheiten aufgrund erhoehter blutfettwerte | |
DE69300037D1 (de) | Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria. | |
DE69424415D1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit | |
ATE263565T1 (de) | Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten | |
ATE186640T1 (de) | Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen | |
HK1009938A1 (en) | Product comprising rapamycin or particular derivatives and an nmda or ampa antagonist for use for the treatment of epilepsy or huntington's disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or huntington's disease | |
DE69625819T2 (de) | Die verwendung von ondansetron zur herstellung eines medikamentes zur behandlung von tremor | |
ATE245982T1 (de) | Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten | |
DE69431320T2 (de) | Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |